Q3 2025 · 13F-HR
Deep Track Capital, LPholdings as filed
Filed 2025-11-14 · accession 0001856083-25-000006
$3.58B
Reported value
56
Positions
2025-09-30
Period end
The Brief · Deep Track Capital, LP · Q3 2025
AI · grounded in 13F
Deep Track Capital, LP initiated a new position in Guardant Health Inc GH valued at $259.5M. The fund also established new stakes in Ionis Pharmaceuticals Inc IONS for $249.1M and Cytokinetics Inc CYTK for $236.3M. Additional new positions include Akero Therapeutics Inc AKRO and Apellis Pharmaceuticals Inc APLSUSD.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 40131M109 | GH | GUARDANT HEALTH INC | $259.5M | 7.24% | 4,154,086 | Common | SOLE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $249.1M | 6.95% | 3,808,144 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $236.3M | 6.60% | 4,300,000 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $190.0M | 5.30% | 4,000,978 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $181.0M | 5.05% | 8,000,382 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $178.3M | 4.98% | 3,000,000 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $156.8M | 4.38% | 9,728,845 | Common | SOLE |
| 268158201 | DVAX | DYNAVAX TECHNOLOGIES CORP | $156.2M | 4.36% | 15,726,349 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $139.5M | 3.89% | 11,932,137 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $137.5M | 3.84% | 9,356,171 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $118.0M | 3.29% | 4,215,811 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $116.1M | 3.24% | 5,380,449 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $114.0M | 3.18% | 1,715,691 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $109.3M | 3.05% | 900,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $108.1M | 3.02% | 3,000,000 | Common | SOLE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC | $102.4M | 2.86% | 3,948,910 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $65.4M | 1.82% | 1,800,000 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $62.3M | 1.74% | 1,200,000 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $56.3M | 1.57% | 41,096,522 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $56.3M | 1.57% | 7,495,000 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $56.0M | 1.56% | 6,057,024 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $55.1M | 1.54% | 3,150,000 | Common | SOLE |
| 30063P105 | EXK | EXACT SCIENCES CORP | $54.7M | 1.53% | 1,000,000 | Common | SOLE |
| 50180M108 | LBRX | LB PHARMACEUTICALS INC | $52.9M | 1.48% | 3,352,804 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $51.7M | 1.44% | 2,000,000 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $51.1M | 1.42% | 2,654,781 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $48.2M | 1.34% | 1,200,000 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $45.0M | 1.26% | 7,859,648 | Common | SOLE |
| 00182C103 | ANIP | ANI PHARMACEUTICALS INC | $41.2M | 1.15% | 450,000 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS INC | $38.3M | 1.07% | 2,426,657 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $34.0M | 0.95% | 3,470,172 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $28.7M | 0.80% | 300,000 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $28.2M | 0.79% | 483,092 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $25.3M | 0.71% | 2,000,000 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $19.7M | 0.55% | 2,279,892 | Common | SOLE |
| 75382E208 | RAPT | RAPT THERAPEUTICS INC | $19.4M | 0.54% | 751,422 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $17.9M | 0.50% | 1,250,000 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $17.7M | 0.49% | 1,500,000 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $15.3M | 0.43% | 2,239,353 | Common | SOLE |
| 372303206 | GMAB | GENMAB A/S | $14.8M | 0.41% | 481,267 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $12.2M | 0.34% | 1,454,562 | Common | SOLE |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $7.2M | 0.20% | 7,419,355 | Common | SOLE |
| 45175G207 | IMA | IMAGENEBIO INC | $7.2M | 0.20% | 878,516 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $6.4M | 0.18% | 549,439 | Common | SOLE |
| 23256X407 | HELP | CYBIN INC | $5.9M | 0.16% | 1,000,000 | Common | SOLE |
| 21900C308 | CRMD | CORMEDIX INC | $5.8M | 0.16% | 500,000 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $5.5M | 0.15% | 1,200,000 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $5.4M | 0.15% | 453,686 | Common | SOLE |
| 01626L204 | ALGS | ALIGOS THERAPEUTICS INC | $4.4M | 0.12% | 444,110 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $4.2M | 0.12% | 2,568,613 | Common | SOLE |
| 98420X202 | XFOR | X4 PHARMACEUTICALS INC | $3.8M | 0.11% | 1,122,484 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $2.2M | 0.06% | 105,085 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $1.8M | 0.05% | 144,600 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $1.3M | 0.04% | 24,856 | Common | SOLE |
| G9TY5A101 | ZURA | ZURA BIO LTD | $1.1M | 0.03% | 259,014 | Common | SOLE |
| 28658R106 | CLYM | CLIMB BIO INC | $1.0M | 0.03% | 509,789 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.